Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chloe Kent

Reporter

London, UK

Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.

Latest From Chloe Kent

Advanz Zeroes In On Innovative Assets And M&A

Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.

Value-Added Medicines M & A

Sun Pharma Reinforces Position As Indian Industry Leader

Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.

Sales & Earnings Research & Development

India Business Makes Gains At Glenmark While Rest Of World Sees Mixed Results

Glenmark’s domestic business was seen to gradually strengthen its market share during Q2, while its North American division saw a minor decline in growth and a drop in COVID-related sales took its toll.

Sales & Earnings Generic Drugs

Tough Times Ahead For Towa As Japanese Generics Giant Slashes 2023 Predictions

Towa has made substantial cuts to its 2023 financial guidance as the difficult conditions of the Japanese generics market begin to take their toll.

Sales & Earnings Generic Drugs

Beximco Faces Potentially Rough Ride In The Face Of Macroeconomic Headwinds

Following a year of impressive business developments, economic developments such as a depreciating local currency threaten to knock Beximco off-course.

Sales & Earnings Generic Drugs

Negotiators Prioritize Generic And Biosimilar Oncology Medicines Over Newer Drugs

The Union for International Cancer Control and the World Health Organization are prioritizing off-patent drugs in their efforts to facilitate oncology medicine access in developing nations.

Biosimilars Generic Drugs
See All
UsernamePublicRestriction

Register